Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
330.34
+11.49 (3.60%)
At close: Apr 6, 2026, 4:00 PM EDT
320.61
-9.73 (-2.95%)
After-hours: Apr 6, 2026, 7:56 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 27 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $471.93, which forecasts a 42.86% increase in the stock price over the next year. The lowest target is $330 and the highest is $583.
Price Target: $471.93 (+42.86%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 13 | 13 | 13 | 12 |
| Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Hold | 4 | 5 | 5 | 5 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 29 | 28 | 28 | 29 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $425 | Strong Buy | Maintains | $425 | +28.66% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $510 | Strong Buy | Reiterates | $510 | +54.39% | Mar 25, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $522 → $330 | Strong Buy → Hold | Downgrades | $522 → $330 | -0.10% | Mar 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $510 | Strong Buy | Reiterates | $510 | +54.39% | Feb 18, 2026 |
| Freedom Broker | Freedom Broker | Hold → Strong Buy Upgrades $470 → $410 | Hold → Strong Buy | Upgrades | $470 → $410 | +24.11% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
5.68B
from 3.71B
Increased by 52.99%
Revenue Next Year
7.49B
from 5.68B
Increased by 31.77%
EPS This Year
7.46
from 2.33
Increased by 220.23%
EPS Next Year
11.16
from 7.46
Increased by 49.58%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.5B | 9.5B | |||
| Avg | 5.7B | 7.5B | |||
| Low | 5.1B | 6.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 74.0% | 66.8% | |||
| Avg | 53.0% | 31.8% | |||
| Low | 37.4% | 14.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.77 | 15.74 | |||
| Avg | 7.46 | 11.16 | |||
| Low | 4.79 | 7.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 362.4% | 110.9% | |||
| Avg | 220.2% | 49.6% | |||
| Low | 105.7% | 1.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.